XML 62 R40.htm IDEA: XBRL DOCUMENT
v3.25.2

SHARE CAPITAL (Tables) | 12 Months Ended
--- | ---
Mar. 31, 2025
Disclosure of terms and conditions of share-based payment arrangement [line items] |
Disclosure of share purchase warrants outstandin [Table Text Block] |
|  | Exercise |  |  | Grant Date |  |  | March 31, |
|  | Price |  |  | Fair Value |  |  | 2025 |
Expiry Date |  | $ |  |  | $ |  |  | # |
August 19, 2026 |  | 3.00 |  |  | 89,737 |  |  | 1,180,750 |
Disclosure of summary of warrants activity [Table Text Block] |
|  | Year ended March 31, 2025 |
|  | Number |  |  | Weighted average exercise price |
|  |  |  |  | $ |
Balance, beginning of year |  | - |  |  | - |
Granted |  | 1,180,750 |  |  | 3.00 |
Exercised |  | - |  |  | - |
Expired |  | - |  |  | - |
Balance, end of year |  | 1,180,750 |  |  | 3.00 |
Disclosure of detailed information about options, valuation assumptions [Table Text Block] |
| Triera | The Company
| Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2025 | Mar 31, 2024
Expected dividend yield | 0% | 0% | 0% | 0%
Expected volatility | 98% to 120% | 98% to 120% | 62% to 77% | 70% to 90%
Expected forfeiture rate | 0% | 0% | 7% | 5%
Risk-free interest rate | 4.50% | 3.90% | 4.0% to 4.5% | 3.6% to 4.5%
Expected life | 3 years | 3 to 5 years | 3 to 5 years | 3 to 5 years
Disclosure of share-based payment reserve [Table Text Block] |
|  | Year |  |  | Year |
|  | Ended |  |  | Ended |
|  | March 31, |  |  | March 31, |
|  | 2025 |  |  | 2024 |
|  | $ |  |  | $ |
Share-based compensation expense |  | 1,529,934 |  |  | 1,786,453 |
Disclosure of stock option and share-based payment activity [Table Text Block] |
|  | Year ended |  |  | Year ended |
|  | March 31, 2025 |  |  | March 31, 2024 |
|  |  |  |  | Weighted |  |  |  |  |  | Weighted |
|  |  |  |  | average |  |  |  |  |  | average |
|  | Number |  |  | exercise price |  |  | Number |  |  | exercise price |
|  |  |  |  | $ |  |  |  |  |  | $ |
Balance, beginning of year |  | 7,098,334 |  |  | 2.37 |  |  | 8,673,334 |  |  | 2.03 |
Granted |  | 2,000,000 |  |  | 1.52 |  |  | 1,250,000 |  |  | 2.03 |
Exercised |  | (1,700,000 | ) |  | 0.45 |  |  | (2,000,000 | ) |  | 0.54 |
Expired |  | (1,275,000 | ) |  | 3.84 |  |  | (825,000 | ) |  | 2.72 |
Balance, end of year |  | 6,123,334 |  |  | 2.32 |  |  | 7,098,334 |  |  | 2.37 |
Disclosure of outstanding options to acquire common shares [Table Text Block] |
|  | Options Outstanding |  |  | Options Exercisable |
|  |  |  |  | Weighted |  |  | Weighted |  |  |  |  |  | Weighted |
|  | Number |  |  | Average |  |  | Average |  |  | Number |  |  | Average |
|  | Outstanding |  |  | Remaining |  |  | Exercise |  |  | Outstanding |  |  | Exercise |
Range of exercise Prices |  | as at Mar 31, |  |  | Contractual |  |  | Price |  |  | as at Mar 31, |  |  | Price |
CAD$ |  | 2025 |  |  | Life (years) |  |  | CAD$ |  |  | 2025 |  |  | CAD$ |
$0.40 - $1.00 |  | 633,334 |  |  | 0.28 |  | $ | 0.55 |  |  | 633,334 |  | $ | 0.55 |
$1.01 - $4.00 |  | 4,465,000 |  |  | 2.75 |  | $ | 2.12 |  |  | 3,135,416 |  | $ | 2.37 |
$4.01 - $5.67 |  | 1,025,000 |  |  | 1.79 |  | $ | 4.27 |  |  | 1,025,000 |  | $ | 4.27 |
Totals |  | 6,123,334 |  |  | 2.33 |  | $ | 2.32 |  |  | 4,793,750 |  | $ | 2.54 |
|  | Options Outstanding |  |  | Options Exercisable |
|  |  |  |  | Weighted |  |  | Weighted |  |  |  |  |  | Weighted |
|  | Number |  |  | Average |  |  | Average |  |  | Number |  |  | Average |
|  | Outstanding |  |  | Remaining |  |  | Exercise |  |  | Outstanding |  |  | Exercise |
Range of exercise Prices |  | as at Mar 31, |  |  | Contractual |  |  | Price |  |  | as at Mar 31, |  |  | Price |
CAD$ |  | 2024 |  |  | Life (years) |  |  | CAD$ |  |  | 2024 |  |  | CAD$ |
$0.40 - $1.00 |  | 2,333,334 |  |  | 0.79 |  | $ | 0.48 |  |  | 2,333,334 |  | $ | 0.48 |
$1.01 - $4.00 |  | 3,025,000 |  |  | 2.52 |  | $ | 2.63 |  |  | 2,316,667 |  | $ | 2.81 |
$4.01 - $5.67 |  | 1,740,000 |  |  | 2.04 |  | $ | 4.46 |  |  | 1,740,000 |  | $ | 4.46 |
Totals |  | 7,098,334 |  |  | 1.84 |  | $ | 2.37 |  |  | 6,390,001 |  | $ | 2.41 |
Triera Biosciences Ltd [Member] |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
Disclosure of stock option and share-based payment activity [Table Text Block] |
|  | Year ended |  |  | Year ended |
|  | March 31, 2025 |  |  | March 31, 2024 |
|  |  |  |  | Weighted |  |  |  |  |  | Weighted |
|  |  |  |  | average |  |  |  |  |  | average |
|  | Number |  |  | exercise price |  |  | Number |  |  | exercise price |
|  |  |  |  | $ |  |  |  |  |  | $ |
Balance, beginning of year |  | 195,000 |  |  | 1.00 |  |  | - |  |  | - |
Granted |  | 5,000 |  |  | 1.00 |  |  | 195,000 |  |  | 1.00 |
Exercised |  | - |  |  | - |  |  | - |  |  | - |
Expired |  | (10,000 | ) |  | 1.00 |  |  | - |  |  | - |
Balance, end of year |  | 190,000 |  |  | 1.00 |  |  | 195,000 |  |  | 1.00 |
Disclosure of outstanding options to acquire common shares [Table Text Block] |
|  | Options Outstanding |  |  | Options Exercisable |
|  |  |  |  | Weighted |  |  | Weighted |  |  |  |  |  | Weighted |
|  | Number |  |  | Average |  |  | Average |  |  | Number |  |  | Average |
|  | Outstanding |  |  | Remaining |  |  | Exercise |  |  | Outstanding |  |  | Exercise |
Range of exercise Prices |  | as at Mar 31, |  |  | Contractual |  |  | Price |  |  | as at Mar 31, |  |  | Price |
CAD$ |  | 2025 |  |  | Life (years) |  |  | CAD$ |  |  | 2025 |  |  | CAD$ |
$0.00 - $1.00 |  | 200,000 |  |  | 3.22 |  | $ | 1.00 |  |  | 196,666 |  | $ | 1.00 |
|  | Options Outstanding |  |  | Options Exercisable |
|  |  |  |  | Weighted |  |  | Weighted |  |  |  |  |  | Weighted |
|  | Number |  |  | Average |  |  | Average |  |  | Number |  |  | Average |
|  | Outstanding |  |  | Remaining |  |  | Exercise |  |  | Outstanding |  |  | Exercise |
Range of exercise Prices |  | as at Mar 31, |  |  | Contractual |  |  | Price |  |  | as at Mar 31, |  |  | Price |
CAD$ |  | 2024 |  |  | Life (years) |  |  | CAD$ |  |  | 2024 |  |  | CAD$ |
$0.00 - $1.00 |  | 195,000 |  |  | 4.25 |  | $ | 1.00 |  |  | 65,000 |  | $ | 1.00 |

X
- Definition Additional information about share-based payment arrangements necessary to satisfy the disclosure requirements of IFRS 2. [Refer: Types of share-based payment arrangements [domain]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 52 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_52&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 45 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 45 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 45 -Subparagraph d -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of detailed information about options, valuation assumptions [Table Text Block] + References No definition available. + Details
Name: | ztek_DisclosureOfDetailedInformationAboutOptionsValuationAssumptionsExplanatory
Namespace Prefix: | ztek_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of share purchase warrants outstanding. + References No definition available. + Details
Name: | ztek_DisclosureOfSharePurchaseWarrantsOutstandingTextBlock
Namespace Prefix: | ztek_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ztek_TrieraBiosciencesLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |